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Objective
To compare the efficacy and safety of frovatriptan and
almotriptan in women with menstrually related migraine
(IHS Classification of Headache disorders) enrolled in a
multicenter, randomized, double blind, cross-over study.
Methods
Patients received frovatriptan 2.5 mg or almotriptan 12.5
mg in a randomized sequence: after treating 3 episodes
of migraine in no more than 3 months with the first
treatment, the patient switched to the other treatment.
Results
67 of the 96 female patients of the intention-to-treat popu-
lation of the main study had regular menstrual cycles and
were thus included in this subgroup analysis. 77 migraine
attacks classified as related to menses were treated with
frovatriptan and 78 with almotriptan. Rate of pain relief at
2- and 4-hrs was 36% and 53% for frovatriptan and 41% and
50% for almotriptan (p=NS between treatments). Rate of
pain free at 2- and 4-hrs was 19% and 47% with frovatriptan
and 29% and 54% for almotriptan (p=NS). At 24-hrs, 62%
of frovatriptan- and 67% of almotriptan-treated patients
had pain relief, while 60% vs. 67% were pain free (p=NS).
Recurrence at 24-hrs was significantly (p<0.05) lower with
frovatriptan (8% vs. 21% almotriptan). This was the case
also at 48-hrs (9% vs. 24%, p<0.05).
Conclusions
Frovatriptan was as effective as almotriptan in the
immediate treatment of menstrually related migraine
attacks. However, it showed a more favorable sustained
effect, as shown by a lower rate of migraine recurrence.
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